Drug intelligence / Profile preview

gastrografin + povidone-iodine

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Rectal
01

Overview

Gastrografin + povidone-iodine is a combination of two agents used for gastrointestinal procedures. Gastrografin is a water-soluble, iodinated radiopaque contrast medium containing sodium amidotrizoate and meglumine amidotrizoate (also known as diatrizoate sodium and diatrizoate meglumine). It is primarily used to enhance the visibility of the gastrointestinal tract during X-ray or CT imaging by increasing radiodensity due to its high iodine content. Gastrografin acts mainly as a diagnostic agent with minimal pharmacological effects, though it can exert a mild laxative effect because of its high osmolarity[1][2][3][4]. Povidone-iodine is an antiseptic solution widely used for disinfection and infection prevention in medical procedures; it releases free iodine, which rapidly kills bacteria, viruses, fungi, and protozoa on contact. The combination may be employed in specific clinical settings where both radiographic visualization and local antisepsis are desired (for example, in certain interventional or post-surgical GI procedures), but this use is not standard or widely documented in major guidelines.

Beyond the preview

Go deeper on gastrografin + povidone-iodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gastrografin + povidone-iodine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call